News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

PDF 202 KB


Berlin, Germany, March 30, 2016 – Epigenomics AG, Berlin, Germany,
(Frankfurt Prime Standard: ECX; ISIN: DE000A11QW50) announces that it has
entered a strategic license agreement with BioChain on the development and
commercialization of a novel, blood-based lung cancer test for China.

BioChain will initiate a clinical trial to validate the lung cancer
detection test with the goal to gain market approval by the CFDA. The trial
is expected to start in 2016. The product development will be based on
Epigenomics’ novel panel of blood-based DNA methylation biomarkers that has
shown promising results in a clinical validation study.

Under the terms of the agreement, Epigenomics will receive undisclosed
upfront, milestone and minimum annual payments as well as mid single-digit
royalty on future revenues. Lung cancer diagnosis remains challenging
worldwide. In view of the high, rapidly growing prevalence of lung cancer
among the Chinese population, the commercialization of a novel, blood-based
test represents a major business opportunity for both companies.
Epigenomics is entitled to commercialize this product in other markets
outside China.

– End of Ad hoc –

Contact Epigenomics AG

Peter Vogt, Investor & Public Relations
Epigenomics AG
Geneststraße 5
10829 Berlin
Phone +49 (0) 30 24345 386

Epigenomics legal disclaimer
This communication expressly or implicitly contains certain forward-looking
statements concerning Epigenomics AG and its business. Such statements
involve certain known and unknown risks, uncertainties and other factors
which could cause the actual results, financial condition, performance or
achievements of Epigenomics AG to be materially different from any future
results, performance or achievements expressed or implied by such
forward-looking statements. Epigenomics AG is providing this communication
as of this date and does not undertake to update any forward-looking
statements contained herein as a result of new information, future events
or otherwise.

The information contained in this communication does not constitute nor
imply an offer to sell or transfer any product, and no product based on
this technology is currently available for sale by Epigenomics in the
United States or Canada. The analytical and clinical performance
characteristics of any Epigenomics product based on this technology which
may be sold at some future time in the U.S. have not been established.